Efficacy and (pharmaco)kinetics of one single dose of rasburicase in patients with chronic kidney disease

Nephron - Clinical Practice

Volumn 108, Issue 4, 2008, Pages

  Sestigiani, E ^a   Mandreoli, M ^a   Guardigli, M ^b   Roda, A ^b   Ramazzotti, E ^c   Boni, P ^c   Santoro, A ^a  

^a Malpighi Hospital   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Chronic kidney disease; Hyperuricemia; Rasburicase

Indexed keywords

RASBURICASE; URIC ACID;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HUMAN; HYPERURICEMIA; MALE; PRIORITY JOURNAL; SINGLE DRUG DOSE; URIC ACID BLOOD LEVEL;

ADULT; AGED; CHEMILUMINESCENT MEASUREMENTS; FEMALE; HUMANS; HYPERURICEMIA; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; URATE OXIDASE; URIC ACID;

EID: 44249086429     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000126906     Document Type: Article

References (37)

1. Oda M, Satta Y, Takenaka O, Takahata N: Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 2002;19:640-653.
2. Sturge RT, Scott JT, Kennedy AC, Hart DP, Buchanan WW: Serum uric acid in England and Scotland. Ann Rheum Dis 1977;36:420-427.
3. Vazquez-Mellado J, Hernandez EA, Burgos-Vargas R: Primary prevention in Rheumatology: the importance of hyperuricemia. Best Pract Res Clin Rheumatol 2004;18:111-124.
4. Armstrong KA, Johnson DW, Campbell SB, Isbel NM, Hawley CM: Does uric acid have a pathogenetic role in graft dysfunction and hypertension in renal transplant recipients? Transplantation 2005;80:1565-1571.
5. Zürcher RM, Bock HA, Thiel G: Hyperuricemia in cyclosporine-treated patients: GFR-related effect. Nephrol Dial Transplant 1996;11:153-158.
6. Perico N, Codreanu I, Caruso M, Remuzzi G: Hyperuricemia in kidney transplantation;in Ronco C, Rodeghiero F (eds): Hyperuricemic Syndromes: Pathophysiology and Therapy. Contrib Nephrol. Basel, Karger, 2005, vol 147, pp 124-131.
7. Gerhardt U, Grosse Hüttmann M, Hohage H: Influence of hyperglycemia and hyperuricemia on long-term transplant survival in kidney transplant recipients. Clin Transplant 1999;13:375-379.
8. Mazzali M, Kim YG, Suga S, Gordon KL, Kang DH, Jefferson JA, Hughes J, Kivlighn SD, Lan HY, Johnson RJ: Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation 2001;71:900-905.
9. Fang J, Alderman MH: Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000;283:2404-2410.
10. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P: Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000;36:1072-1078.
11. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, Lakka TA, Salonen JT: Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004;164:1546-1551.
12. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ: Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002;282:F991-F997.
13. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RS: A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002;13:2888-2897.
14. Syrjanen J, Mustonen J, Pasternack A: Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000;15:34-42.
15. Ohno I, Osoya T, Gomi H, Ichida K, Okabe H, Hikita M: Serum uric acid and renal prognosis in IgA nephropathy. Nephron 2001;87:333-339.
16. Wortmann RL: Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 2005;17:319-324.
17. Vazquez-Mellado J, Meono Morales E, Pacheco-Tena C, Burgos-Vargas R: Relationship between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-983.
18. Vogt B: Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant 2005;20:431-433.
19. Guardigli M, Sestigiani E, Mandreoli M, Ramazzotti E, Santoro A, Roda A: A sensitive chemiluminescence assay for the evaluation of urate oxidase activity after ad ministration of rasburicase. Personal communication at 11th Meeting on Recent Developments in Pharmaceutical Analysis, Rimini, 2005.
20. Stigbrand M, Jonsson T, Ponten E, Irgum K, Bos R: Mechanism and applications of peroxyoxalate chemiluminescence;in Garcia-Campana AM, Baeyens WRG (eds): Chemiluminescence in Analytical Chemistry. New York, Dekker, 2001, pp 141-174.
21. Ueng S: Rasburicase (Elitek): a novel agent for tumor lysis syndrome. Proc (Bayl Univ Med Cent) 2005;18:275-279.
22. Fraisse L, Bonnet MC, de Farcy JP, Agut C, Dersigny D, Byaol A: A colorimetric 96-well microtiter plate assay for the determination of urate oxidase activity and its kinetic parameters. Anal Biochem 2003;309:173-179.
23. Stamp LK, O'Donnell JL, Chapman PT: Emerging therapies in the long-term management of hyperuricaemia and gout. Intern Med J 2007;37:258-266.
24. Arai M, Yokusuka O, Fujiwara K, Kojima H, Kanda T, Hirasawa H: Fulminant hepatic failure associated with benzbromarone treatment: a case report. J Gastroenterol Hepatol 2002;17:625-626.
25. Jansen TL, Reinders MK, van Roon EN, Brouwers JR: Benzbromarone withdrawn from the European market: another case of 'absence of evidence is evidence of absence'? Clin Exp Rheumatol 2004;22:651.
26. Becker MA, Schumacher HR, Wortmann R, MacDonald P, Palo W, et al: Febuxostat compared with allopurinol in patients with hyperuricaemia and gout. N Engl J Med 2005;353:2450-2461.
27. Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B: Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001;19:697-704.
28. Coiffier B, Mounier N, Bologna S, Fermé C, Tilly H, Sonet A, et al;Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma: Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003;21:4402-4406.
29. Gutiérrez-Macías A, Lizarraldes-Palacios E, Martínez-Odriozola P, Miguel-De la Villa F: Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricemia. BMJ 2005;331:623-624.
30. Terkeltaub RA: Gout. N Engl J Med 2003;349:1647-1655.
31. Perlstein TS, Gumieniak O, Williams GH, Sparrow D, Cokonas PS, Graziano M, et al: Uric acid and the development of hypertension. The Normative Aging Study. Hypertension 2006;48:1031-1036.
32. Johnson RJ, Feig DI, Khang DH, Herrera-Acosta J: Resurrection of uric acid as a causal factor for essential hypertension. Hypertension 2005;45:18-28.
33. Bos MJ, Koudstaal PJ, Hofman A, Witteman JCM, Breteler MMB: Uric acid is a risk factor for myocardial infarction and stroke. The Rotterdam study. Stroke 2006;37:1503-1507.
34. Iseki K, Ikemiya Y, Inoue T, Iseki C, Iseki C, Kinjo K, Takishita S: Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004;44:642-650.
35. Siu YP, Leung KT, Tong MKH, Kwan TH: Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006;47:51-59.
36. Ames BN, Cathcart R, Schwiers E, et al: Uric acid provides an antioxidant defence against oxidant and radical caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981;78:6858-6862.
37. Chenson BD, Dutcher BS: Managing malignancy-associated hyperuricemia with rasburicase. J Support Oncol 2005;3:117-124.